GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

lusvertikimab   Click here for help

GtoPdb Ligand ID: 9604

Synonyms: Effi-7 | MD-707 | OSE-127 | OSE127
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lusvertikimab (OSE-127) is a humanized monoclonal antibody that targets the alpha chain of the interleukin 7 receptor (CD127; IL7R). It antagonises IL-7R signalling by T effector cells, thus down regulating their contribution to the immune response. It was proposed to treat autoimmune diseases, transplant rejection and as an immuno-oncology candidate [2,5]. It is likely one of the candidates claimed in patent WO2015189302 [4].
Click here for help
Immunopharmacology Comments
IL-7Rα is expressed on effector T (Teff) cells, but not on regulatory T (Treg) cells. IL- 7 is a cytokine which specifically regulates the tissue migration of human Teff cells, especially in the gut [6] and skin. Blocking this receptor prevents the migration of pathogenic Teff cells to the intestinal mucosa, but preserves Treg function, thereby retaining their positive impact in autoimmune diseases such as ulcerative colitis. Belarif et al. (2018) reported preclinical efficacy of antagonistic anti-IL-7Rα monocloncals in a non-human primate model of autoimmune chronic skin inflammation [1].